Target Library by Binder Type

• All Binder Types

  Biocytogen's comprehensive, fully human antibody portfolio spans diverse binder formats. We support a wide range of discovery needs—from high-affinity monoclonals and plug-and-play bispecific formats to compact VHH molecules with deep tissue penetration, as well as antibodies targeting hard-to-drug GPCRs and other challenging targets.

  Featured targets: CDH6,LY6G6D,ASGR1

• Regular Monoclonal Antibody

  Monoclonal antibodies generated from RenMab mice offer high diversity and affinity, require no humanization, and are widely used across oncology, autoimmune, metabolic, and other therapeutic areas.

  Featured targets: C5a,ALPL

• Common Light Chain Antibody

  Common light chain antibodies share a single light chain, preventing heavy–light chain mispairing and simplifying bispecific assembly to near-monoclonal efficiency. Biocytogen has developed antibody scaffolds covering 200+ TAA targets, enabling plug-and-play rapid screening and validation of bispecific antibodies and bispecific ADC therapies.

  Featured targets: ALPL,CDH6

• HCAb/VHH Antibody;VHH

  VHH antibodies are compact, stable, and highly penetrant, enabling efficient delivery into tumors and across the blood–brain barrier. Their simple architecture reduces manufacturing complexity, making them ideal components for bispecific antibodies, multispecific formats, and cell therapies.

  Featured targets: C5a,ALPL

• Anti-GPCR Antibody

  GPCR-targeting antibodies can modulate signaling pathways and eliminate diseased cells via ADCC/ADCP. However, GPCRs have historically been challenging to drug with antibodies. Leveraging our proprietary RenMice® technology, Biocytogen delivers high-affinity, high-specificity human GPCR antibodies—including mono- and bispecific formats—to advance oncology and metabolic therapies.

  Featured targets: ALPL,CDH6